Patents Assigned to Inserm
  • Methods for the Screening of Antibacterial Substances
    Publication number: 20090311714
    Abstract: The present invention concerns a method for the screening of antibacterial substances comprising a step of determining the ability of a candidate substance to inhibit the activity of a purified enzyme selected from the group consisting of: (i) a D-aspartate ligase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 to SEQ ID No 10, or a biologically active fragment thereof; and (ii) a L,D-transpeptidase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with the amino acid sequence of SEQ ID No 11, or a biologically active fragment thereof.
    Type: Application
    Filed: August 1, 2006
    Publication date: December 17, 2009
    Applicants: UNIVERSITE RENE DESCARTES, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean-Luc Mainardi, Laurent Gutmann, Michel Arthur, Samuel Bellais, Jean Emmanuel Hugonnet, Claudine Mayer, Sabrina Biarotte-Sorin
  • Method For Expressing Polypeptides In Eukaryotic Cells Using Alternative Splicing
    Publication number: 20090305343
    Abstract: This invention relates to an expression cassette for expressing polypeptides in eukaryotic cells using alternative splicing. The expression cassette comprises in 5? to 3? downstream direction: a promoter; a sequence transcribed in a 5? untranslated region (5?UTR); a donor splice site; an intron; a first acceptor splice site; a first cistron encoding a first polypeptide; a second acceptor splice site; a second cistron encoding a second polypeptide; an internal ribosome entry site (IRES) operably linked to a selection marker; and a sequence transcribed in a 3? untranslated region (3?UTR) including a polyadenylation signal, wherein the polyadenylation signal is unique.
    Type: Application
    Filed: May 16, 2007
    Publication date: December 10, 2009
    Applicants: MILLEGEN, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Stéphanie Fallot, Abdelhakim Kharrat, Philippe Mondon, Khalil Bouayadi, Patrick Brune, Hervé Prats, Christian Touriol
  • IMPORTATION OF MITOCHONDRIAL PROTEIN BY AN ENHANCED ALLOTOPIC APPROACH
    Publication number: 20090306188
    Abstract: The inventors demonstrate that mRNA sorting to the mitochondrial surface is an efficient way to proceed to such an allotopic expression, and that this mRNA sorting can be controlled by selecting appropriate mitochondrion-targeting sequence (MTS) and appropriate 3?UTR sequences. The CDS sequence which codes for the protein to be delivered into the mitochondrion is guided by these appropriate MTS and 3?UTR sequences from the nuclear compartment to the mitochondrion-bound polysomes (where the CDS is translated), and aids in an efficient translocation of a mature functional protein into the mitochondria. Appropriate MTS and 3?UTR sequences correspond to those of nuclearly-transcribed mitochondrially-targeted mRNAs. The inventors demonstrate that, to obtain a stable therapeutically-effective importation, both an appropriate MTS and an appropriate 3?UTR should preferably be used.
    Type: Application
    Filed: May 3, 2006
    Publication date: December 10, 2009
    Applicant: INSERM (INSTITUT NATIONAL DE AL SANTE ET DE AL REC
    Inventors: Marisol Corral-Debrinski, José-Alain Sahel, Valérie Kaltimbacher, Crystel Bonnet
  • Peptides derived from the protein MMP-2, and the use thereof in antitumoral immunotherapy
    Patent number: 7629439
    Abstract: Peptides derived from MMP-2 metalloproteinase that form T cell epitopes when presented by MHC Class I molecules. Anti-tumor therapy using these peptides.
    Type: Grant
    Filed: June 24, 2004
    Date of Patent: December 8, 2009
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale, Universite de Nantes
    Inventors: Yannick Guilloux, Francine Jotereau, Emmanuelle Godefroy, Elisabeth Diez, Agnès Aubry
  • ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS
    Publication number: 20090292021
    Abstract: Pharmaceutical compositions including, as the active ingredients, a combination of vigabatrin and of at least one substance having anti-ischemic effect, are disclosed.
    Type: Application
    Filed: July 31, 2007
    Publication date: November 26, 2009
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC
    Inventors: Serge Picaud, Agnes Duboc, Michel Paques, Jose Sahel, Manuel Simonutti
  • METHODS FOR ANALYZING DIFFERENTIAL GENE EXPRESSION ASSOCIATED WITH MYELOPROLIFERATIVE DISORDERS (MPD) CANCER DISEASE
    Publication number: 20090286689
    Abstract: The present application relates to gene analysis and, in particular, to gene expression profiling for identifying molecular signature of cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer and studying cancer. More particularly, the application is directed to a method for analyzing differential gene expression associated with cancer disease, in particular the G1 phase of the cell cycle, such as myeloproliferative disorders (MPD) or breast cancer comprising detection of upregulation and/or downregulation of a pool of polynucleotide sequences in a cell or tissue sample, said pool corresponding to all or part the polynucleotide sequences, subsequences or complements thereof, of the genes listed in Tables 1, 2 and 3.
    Type: Application
    Filed: December 11, 2007
    Publication date: November 19, 2009
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Daniel BIRNBAUM, Helene Lelievre, Nathalie Cervera
  • DEVICE AND METHOD FOR THE TIME-BASED ANALYSIS OF THE AGITATION OF A BEDRIDDEN PATIENT
    Publication number: 20090281461
    Abstract: Device for the time-based analysis of the agitation of a bedridden patient includes elements (4) for acquiring the patient's shouts and elements (5) for acquiring the patient's movements, the acquisition elements being connected to storage elements (9) suitable for storing the acquired data accompanied by a time stamping of the latter, the storage elements being connected to analysis and presentation elements (10) suitable for providing care staff with a representation of the frequency and duration of the patient's shouts and movements which are representative of the patient's agitation over a determined time span, characterized in that the elements for acquiring shouts include a bandpass filter (6) suitable for isolating the shouts from speech and ambient noise.
    Type: Application
    Filed: September 11, 2007
    Publication date: November 12, 2009
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Francois Steenkeste, Pierre Rumeau
  • LSR RECEPTOR, ITS ACTIVITY, ITS CLONING AND ITS APPLICATIONS TO THE DIAGNOSIS, PREVENTION AND/OR TREATMENT OF OBESITY AND RELATED RISKS OR COMPLICATIONS
    Publication number: 20090263847
    Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.
    Type: Application
    Filed: September 27, 2007
    Publication date: October 22, 2009
    Applicants: Serono Genetics Institute S.A., Institut National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: BERNARD BIHAIN, Lydie Bougueleret, Frances Yen-Potin
  • Method for Predicting Responsiveness to TNF Alpha Blocking Agents
    Publication number: 20090252740
    Abstract: The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNF? blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method.
    Type: Application
    Filed: May 15, 2007
    Publication date: October 8, 2009
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Jean-Philippe Salier, Maryvonne Daveau, Anne-Christine Gauthier-Jauneau, Olivier Vittecoq, Xavier Le Loet, Alain Daragon, Othmane Mejjad, Thierry Lequerre
  • Live Attenuated Bordetella Strains as a Single Dose Vaccine Against Whooping cough
    Publication number: 20090246222
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Application
    Filed: March 7, 2007
    Publication date: October 1, 2009
    Applicants: Institute Pasteur de Lille, Institute National de la Sante de la Recherche Medicale (Inserm)
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Nucleic acids useful for triggering tumor cell lethality
    Patent number: 7595302
    Abstract: The invention relates to double-stranded nucleic acid fragments comprising a chemically modified backbone and at least 4-1000 bp, preferably 8-500 bp, and most preferably 16-200 bp. The disclosed molecules (DRIL molecules) may interfere with DNA damage signaling and repair pathways, in particular the non homologous NHEJ pathway of double-stranded break repair. The invention discloses the application of the DRIL molecules as adjuvant compositions to be used in association with a DNA breaking treatment, particularly radiotherapy or chemotherapy, in combination with a pharmaceutically acceptable carrier, in an efficient amount to be introduced in the tumoral cell nuclei in order to trigger DNA repair induced lethality (DRIL in short) of tumoral cells/tissues.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: September 29, 2009
    Assignees: Institut Curie, Centre National de la Recherche Scientifique (CNRS), Museum National d'Histoire Naturelle, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Marie Dutreix, Jian-Sheng Sun
  • Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2
    Publication number: 20090232826
    Abstract: The invention relates to a monoclonal antibody or a fragment thereof comprising in the H chain variable region at least one complementarity determining region (CDR) selected among CDR1, CDR2 and CDR3 having, respectively, an amino acids sequence set forth as SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 or functional analogues thereof.
    Type: Application
    Filed: May 2, 2005
    Publication date: September 17, 2009
    Applicants: MYMETICS CORPORATION, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Morgane Bomsel, Daniela Tudor
  • Thrombin-cleavable chimeric proteins
    Patent number: 7589178
    Abstract: The invention relates to chimeric proteins comprising an artificial sequence for cleavage by thrombin, in which the activation peptide is fibrinopeptide A. Preferably, said chimeric proteins are derived from the zymogen of a serine protease such as PC or FX, by replacing the activation peptide of said zymogen with fibrinopeptide A, or a portion thereof, comprising at least amino acids P10 to P1 of said fibrinopeptide.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: September 15, 2009
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Le Bonniec, Pierre-Emmanuel Marque, Virginie Louvain, Claire Calmel, Elsa Bianchini, Martine Aiach
  • Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
    Patent number: 7589110
    Abstract: The invention features methods and devices for local delivery of agents that modify glutamate-mediated neurotransmission to the inner ear for treatment of inner ear disorders caused by glutamate-induced hearing loss and/or tinnitus.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: September 15, 2009
    Assignees: Durect Corporation, Inserm
    Inventors: Jean-Luc Puel, Remy Pujol, Yves Christen
  • Derivatives of 4,4?-dithiobis-(3-aminobutane-1-sulfonates) and compositions comprising the same
    Patent number: 7582797
    Abstract: The invention relates to derivatives of 4,4?-dithiobis-(3-aminobutane-1-sulfonates) of formula (1), of use for the treatment and prevention of primary and secondary arterial hypertension.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: September 1, 2009
    Assignee: Institute National de la Sante et de la Recherche Medicale (Inserm)
    Inventors: Bernard Pierre Roques, Nicolas Inguimbert, Marie-Claude Fournie-Zaluski, Pierre Corvol, Catherine Llorens-Cortes
  • Vitro Method for the Prognosis of Progression of a Cancer and of the Outcome in a Patient and Means for Performing Said Method
    Publication number: 20090215053
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Application
    Filed: September 28, 2006
    Publication date: August 27, 2009
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jérôme Galon, Franck Pages, Wolf-Herman Fridman
  • Method for Treating Polyglutamine Expansion Neurodegenerative Diseases
    Publication number: 20090208455
    Abstract: The present invention relates to use of an inducer of Promyelocytic Leukemia protein (PML) expression, and especially PML IV for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases. More specifically, the present invention relates to the use of an interferon polypeptide for the manufacture of a medicament intended for the treatment of polyglutamine expansion neurodegenerative diseases.
    Type: Application
    Filed: June 22, 2007
    Publication date: August 20, 2009
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medical)
    Inventors: Alexandre Janer, Annie Sittler
  • Gene Involved in V(D)J recombination and/or DNA repair
    Publication number: 20090208963
    Abstract: The invention relates to a new gene and protein involved in V(D)J recombination and repair. The invention also relates to methods of diagnosis and therapy using these genes and protein. The invention also relates to transgenic animals over- and under-expressing said gene.
    Type: Application
    Filed: April 21, 2009
    Publication date: August 20, 2009
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Pierre De Villartay, Despina Moshous, Alain Fischer
  • Production of antibody formats and immunological applications of said formats
    Publication number: 20090202979
    Abstract: The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.
    Type: Application
    Filed: June 13, 2007
    Publication date: August 13, 2009
    Applicants: Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Daniel Baty, Ghislaine Behar, Martine Chartier, Andre Pelegrin, Jean-Luc Teillaud, Isabelle Teulon
  • VIROSOME-LIKE VESICLES COMPRISING GP41-DERIVED ANTIGENS
    Publication number: 20090202622
    Abstract: The present invention relates to a virosome-like vesicle comprising at least a gp41-derived antigen or an analogue thereof, said gp41-derived antigen being located to the external surface of and/or encapsulated inside said vesicle and being in a convenient configuration for conferring said virosome-like vesicle with an ability to induce an immune response against a gp41 protein or a human immunodeficiency virus (HIV).
    Type: Application
    Filed: March 2, 2007
    Publication date: August 13, 2009
    Applicants: MYMETICS CORPORATION, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM), PEVION BIOTECH LTD.
    Inventors: Sylvain Fleury, Morgane Bomsel, Rinaldo Zurbriggen